Fetal Personhood & Reproductive Criminalization: Impacts on Health
Ozempic and Cardiovascular risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The data: Key findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33,indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular Event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 2.6 | 1.7 | 1.55 |
| Non-Fatal Heart Attack | 1.9 | 1.3 | 1.47 |
Who is Affected? Understanding the Patient Population
This finding is particularly relevant for individuals with pre-existing cardiovascular disease. The SELECT trial specifically enrolled participants with a history of established cardiovascular disease, including heart attack, stroke, or peripheral artery disease. It’s important to emphasize that the trial did *not* include patients with type 2 diabetes; all participants had obesity but not diabetes. This raises questions about the potential cardiovascular effects of semaglutide in different patient populations.
The average age of participants was 61 years, and approximately half were women. this demographic is increasingly seeking weight loss solutions, making these findings particularly timely and important.
Why Does This Matter? The Implications for Prescribing Practices
The results of the SELECT trial challenge the widely held belief that semaglutide is a safe and effective weight loss medication for all. While the drug demonstrably promotes weight loss, the potential cardiovascular risks in vulnerable populations cannot be ignored. Clinicians should carefully assess the cardiovascular risk profile of patients before initiating semaglutide therapy, particularly those with established heart disease.